A comparative study on conbercept and triamcinolone acetoinde intravitreal injection for macular edema secondary to central retinal vein occlusion

Authors: Ma Fengwei,  Du Cuiyun,  Cheng Meihong,  Ma Yusheng

DOI: 10.3760/cma.j.issn.2095-0160.2016.09.013
Published 2016-09-10
Cite as Chin J Exp Ophthalmol, 2016,34(9): 837-841.

Abstract

Background

Macular edema is one of the serious complications of central retinal vein occlusion (CRVO), and the present therapies are laser coagulation and intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs.Conbercept is humanized-monoclonal VEGF antibody and used for the treatment of retinal vascular diseases.However, fewer studies were focused on its application in macular edema secondary to CRVO.

Objective

The aim of this study was to compare the effectiveness and safety of conbercept with triamcinolone acetonide (TA) by intravitreal injections for macular edema secondary to CRVO.

Methods

A non-randomized controlled study was carried out under the approval of the informed consent of patients.Sixty eyes of 60 patients with macular edema secondary to CRVO were included in Weifang Yidu Central Hospital from March 2012 to August 2013.The eyes were divided into the conbercept group and TA group with 30 for each group.Conbercept and TA of 0.05 ml were intravitreally injected in different groups, and the best corrected visual acuity (BCVA), central macular thickness (CMT) measured by OCT, intraocular pressure (IOP) and relavant complications were examined before injection and 1 week, 1 month, 3 months and 6 months after injection.The treatment outcomes were compared intergrouply and along with time.

Results

The BCVA was evidently better in 1 week, 1 month, 3 months and 6 months after injection than that before injection both in conbercept group and TA group (all at P<0.01), and the BCVA of TA group was better than that of conbercept group 1 week after injection (P<0.05). The CMT values of Conbercept were (572.00±100.01), (325.12±91.55), (280.00±92.37), (258.65±88.65), (300.00±87.64)μm, and those of TA group were (570.00±102.21), (345.12±89.31), (290.00±80.27), (309.65±84.13) and (303.00± 90.59)μm, and CMT value after injection was significantly lower in 1 week, 1 month, 3 months and 6 months after injection than that before injection both in the conbercept group and the TA group (all at P<0.05), and CMT value was evidently reduced in the conbercept group compared with the TA group 3 months after injection (P<0.05). The IOP was (15.20±3.52), (21.20±3.80), (26.40±4.00), (23.60±3.73) and (21.50±3.27)mmHg in the TA group before injection and 1 week, 1 month, 3 months and 6 months after injection, showing significnatly elavation after injection (all at P<0.05), and the IOP at different time points was higher in the TA group than that in the conbercept group (all at P<0.05). However, there was no considerable change of IOP before and after injection in conbercept group (all at P<0.05).

Conclutions

Both conbercept and TA are effective for macular edema secondary to CRVO by intravtreal injection.Compared with TA, conbercept is much safer because of less risk of IOP rising after intravtreal injection.

Key words:

Antibodies, monoclonal, humanized/therapeutic use; Retinal vein occlusion/complications; Macular edema/drug therapy; Conbercept/therapeutic use; Triamcinolone acetoinde/therapeutic use; Intravitreal injections; Treatment outcome; Comparative studies

Contributor Information

Ma Fengwei
Department of Ophthalmology, Yidu Center Hospital of Weifang, Weifang 262500, China
Du Cuiyun
Cheng Meihong
Ma Yusheng
(Read 34 times, 1 visits today)
Updated: October 8, 2019 — 10:16 am